Patent intelligence · US
US 10444237
Anti-pancreatic cancer monoclonal antibody and use thereof
Anti-pancreatic cancer monoclonal antibody and use thereof
Patent details — US 10444237
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 15, 2019
- Expiration
- Oct 10, 2039
- Claims
- 7
- CPC classes
- A61P, A61P35/00
Quick answer
US 10444237 (Anti-pancreatic cancer monoclonal antibody and use thereof) is held by NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.. Status: granted. Granted Oct 15, 2019. Expires Oct 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61P, A61P35/00
More from NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted -
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 10444237?
US 10444237 (Anti-pancreatic cancer monoclonal antibody and use thereof) is held by NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.. Status: granted. Granted Oct 15, 2019. Expires Oct 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10444237?
NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 10444237 expire?
Our index shows an expiration date of Oct 10, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.